Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Familial adenomatous polyposis patients without an identified APC germline mutation have a severe phenotype.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Vaccines against hepatitis C: a travel into neutralisation space

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Authors' response: Association between IBD and Parkinson's disease: seek and you shall find?

    Publikation: Bidrag til tidsskriftKommentar/debatForskning

  1. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
BACKGROUND: Development of more than 100 colorectal adenomas is diagnostic of the dominantly inherited autosomal disease familial adenomatous polyposis (FAP). Germline mutations can be identified in the adenomatous polyposis coli (APC) gene in approximately 80% of patients. The APC protein comprises several regions and domains for interaction with other proteins, and specific clinical manifestations are associated with the mutation assignment to one of these regions or domains. AIMS: The phenotype in patients without an identified causative APC mutation was compared with the phenotype in patients with a known APC mutation and with the phenotypes characteristic of patients with mutations in specific APC regions and domains. PATIENTS: Data on 121 FAP probands and 149 call up patients from 70 different families were extracted from the Danish Polyposis register. METHODS: Differences in 16 clinical manifestations were analysed according to the patient's mutational status. Two sided independent t sample test, two sided chi(2) test, and odds ratios were calculated. RESULTS: Patients without identified APC mutations had a unique and severe phenotype, which was roughly described as: young age at diagnosis and subsequent death in spite of development of few colorectal adenomas; low risk of involvement of the upper gastrointestinal tract, as reflected by a low mean Spigelman stage, and a low risk of fundic gland polyposis. Finally, they had significantly fewer affected family members, although they do not themselves more often represent an isolated case. CONCLUSIONS: The severe phenotype should be considered when counselling FAP families in which attenuated FAP is excluded and in which a causative APC mutation has not been identified.
Bidragets oversatte titelFamilial adenomatous polyposis patients without an identified APC germline mutation have a severe phenotype.
OriginalsprogEngelsk
TidsskriftGut
Vol/bind53
Udgave nummer2
Sider (fra-til)266-270
Antal sider5
ISSN0017-5749
StatusUdgivet - 2004

ID: 32522027